Eli Lilly and Company
$ 1133.00
-2.41%
12 Jun - close price
- Market Cap 1,010,342,953,000 USD
- Current Price $ 1133.00
- High / Low $ 1169.99 / 1132.81
- Stock P/E 40.32
- Book Value 34.92
- EPS 28.10
- Next Earning Report 2026-08-06
- Dividend Per Share $6.23
- Dividend Yield 0.54 %
- Next Dividend Date -
- ROA 0.21 %
- ROE 1.07 %
- 52 Week High 1182.73
- 52 Week Low 619.40
About
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Analyst Target Price
$1215.79
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-04 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-02-06 | 2024-10-30 | 2024-08-08 | 2024-04-30 | 2024-02-06 | 2023-11-02 | 2023-08-08 |
| Reported EPS | 8.55 | 7.54 | 7.02 | 6.29 | 3.06 | 5.32 | 1.18 | 3.92 | 2.58 | 2.49 | 0.1 | 2.11 |
| Estimated EPS | 6.79 | 7.17 | 5.89 | 5.5 | 4.11 | 5.0668 | 1.47 | 2.77 | 2.49 | 2.37 | -0.12 | 1.99 |
| Surprise | 1.76 | 0.37 | 1.13 | 0.79 | -1.05 | 0.2532 | -0.29 | 1.15 | 0.09 | 0.12 | 0.22 | 0.12 |
| Surprise Percentage | 25.9205% | 5.1604% | 19.1851% | 14.3636% | -25.5474% | 4.9972% | -19.7279% | 41.5162% | 3.6145% | 5.0633% | 183.3333% | 6.0302% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 9.01 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-10 | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-10 | 2024-06-10 | 2024-03-08 |
| Amount | $1.73 | $1.73 | $1.5 | $1.5 | $1.5 | $1.5 | $1.3 | $1.3 | $1.3 | $1.3 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LLY
2026-06-14 09:37:30
Epoch Investment Partners Inc. significantly reduced its holdings in CVS Health Corporation by 7% in the fourth quarter, yet still maintains a substantial investment of over $166 million, making CVS its 23rd largest position. Despite insider selling, analysts generally view CVS Health favorably with a "Moderate Buy" consensus and an average price target of $100.68. The company recently surpassed earnings expectations and is actively expanding access to GLP-1 drugs and integrating AI into its operations.
2026-06-14 08:57:16
Aoife Keohane has been promoted to Associate Vice President – HR Technology and Operations at Eli Lilly and Company. She has nearly twelve years of experience with the company, holding various leadership roles in HR operations, technology, and global business services. Keohane's previous roles include Executive Director, Global HR Shared Services, and she possesses a Bachelor's degree in Human Resource Management.
2026-06-14 08:41:14
Restaurant Brands International Inc. (QSR) remains the largest holding for Baupost Group LLC MA, despite a slight reduction in its stake during the fourth quarter. Analysts generally maintain a "Moderate Buy" rating with a consensus price target of $83.54, following better-than-expected quarterly earnings and a 3.5% dividend yield. Insider selling has recently increased, with CEO Joshua Kobza and Jeffrey Housman divesting significant shares.
2026-06-14 07:45:21
Adams Diversified Equity Fund Inc. significantly increased its stake in CVS Health Corporation by 175.5% in the fourth quarter, owning 351,300 shares worth $27.88 million. Other institutional investors also adjusted their holdings, while CVS insiders recently sold a substantial number of shares. The article also highlights recent positive news for CVS, including its expansion of GLP-1 weight-loss drug access, AI integration, and new mental health services, alongside analyst ratings and financial performance data.
2026-06-14 07:45:21
8 Knots Management LLC significantly reduced its stake in CVS Health Corporation (NYSE:CVS) during the fourth quarter, selling 659,963 shares and decreasing its holdings by 56.2%. Despite this, CVS Health remains 8 Knots Management LLC's sixth-largest holding. The article also details other institutional investor activity, CVS Health's financial performance, recent dividend announcements, insider trades, and current analyst ratings, with the company showing strong revenue and EPS growth and a "Moderate Buy" consensus rating from analysts.
2026-06-13 09:15:43
Macquarie Group Ltd. reduced its stake in CVS Health Corporation by 10.1% in the fourth quarter of 2025, selling over 152,000 shares but still holding 1.36 million shares valued at about $107.5 million. This divestment occurred despite CVS Health's strong operational performance, including better-than-expected earnings and a raised FY2026 EPS guidance. While analyst sentiment is generally positive, significant insider selling, particularly by Director Larry Robbins and EVP Tilak Mandadi, has been noted.
